Camden Capital, LLC Allakos Inc. Transaction History
Camden Capital, LLC
- $887 Million
- Q4 2024
A detailed history of Camden Capital, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Camden Capital, LLC holds 11,356 shares of ALLK stock, worth $2,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,356
Previous 11,356
-0.0%
Holding current value
$2,839
Previous $7,000
85.71%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALLK
# of Institutions
79Shares Held
68.8MCall Options Held
20.9KPut Options Held
0-
Bvf Inc San Francisco, CA16.6MShares$4.14 Million0.75% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$1.54 Million0.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.7MShares$1.43 Million0.3% of portfolio
-
Lynx1 Capital Management LP San Juan, PR3.63MShares$907,0361.7% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.59MShares$898,6440.01% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $21.2M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...